Try our beta test site
404 studies found for:    myelodysplastic syndromes | Open Studies
Show Display Options
Rank Status Study
21 Recruiting A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Interventions: Drug: Luspatercept;   Other: Placebo
22 Not yet recruiting Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
Condition: Myelodysplastic Syndromes
Interventions: Drug: Talacotuzumab;   Drug: Daratumumab
23 Recruiting A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy.
Condition: Myelodysplastic Syndrome
Interventions: Procedure: Bone marrow aspirate;   Drug: Deferasirox
24 Not yet recruiting Entinostat and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome After DNMTi Therapy Failure
Condition: Previously Treated Myelodysplastic Syndrome
Interventions: Drug: Entinostat;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
25 Recruiting A Safety and Pharmacology Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Interventions: Drug: Atezolizumab;   Drug: Azacitidine
26 Recruiting Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.
Conditions: Adult Patients With Low Risk Myelodysplastic Syndrome;   Adult Patients With Int 1-risk Myelodysplastic Syndrome
Interventions: Drug: Erythropoietin alpha;   Drug: Deferasirox
27 Recruiting Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Intervention: Drug: selinexor (KPT-330)
28 Recruiting Efficacy of Eltrombopag Plus Lenalidomide Combination Therapy in Patients With IPSS Low and Intermediate-risk Myelodysplastic Syndrome With Isolated del5q
Condition: Myelodysplastic Syndromes
Interventions: Drug: Eltrombopag/Revolade;   Other: Placebo;   Drug: Lenalidomide
29 Recruiting A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)
Conditions: Myelodysplastic Syndromes;   Thrombocytopenia
Intervention: Drug: Eltrombopag
30 Not yet recruiting CB-839 + Azacitidine for Treatment of Myelodysplastic Syndrome (MDS)
Conditions: Myelodysplastic Syndrome;   Other Diseases of Blood and Blood-forming Organs
Interventions: Drug: CB-839;   Drug: Azacitidine
31 Recruiting Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant
Conditions: Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Secondary Myelodysplastic Syndrome
Interventions: Drug: Azacitidine;   Drug: Decitabine;   Other: Quality-of-Life Assessment
32 Recruiting The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)
Condition: Myelodysplastic Syndrome
Interventions: Drug: Oral Azacitidine;   Drug: Placebo
33 Recruiting A Prospective, Multicentre European Registry for Newly Diagnosed Patients With Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes (MDS)
Intervention: Other: No interventions
34 Recruiting Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
Conditions: Myelodysplastic Syndromes;   Acute Myeloid Leukemia;   Chronic Myelomonocytic Leukemia
Intervention: Drug: H3B-8800
35 Recruiting Efficacy and Safety of Ultra Small Dose Decitabine for the Lower Risk MDS Patients With Transfusion Dependent
Condition: Myelodysplastic Syndromes
Intervention: Drug: decitabine
36 Recruiting Safety & Pharmacokinetics of Pegolsihematide for Treatment of Anemia Patient With Myelodysplastic Syndromes
Conditions: Myelodysplastic Syndromes;   Anemia
Intervention: Drug: Pegol-sihematide injection
37 Not yet recruiting Pyrimethamine for Intermediate/High-risk Myelodysplastic Syndromes (MDS) That Has Relapsed or Refractory to Azanucleosides
Condition: Myelodysplastic Syndromes
Intervention: Drug: Pyrimethamine
38 Not yet recruiting Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome
Conditions: Anemia;   Myelodysplastic Syndrome
Interventions: Drug: Deferasirox;   Other: Laboratory Biomarker Analysis
39 Recruiting A Dose Escalation and Cohort Expansion Study of RO6870810/TEN-010 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Condition: Myelodysplastic Syndromes, Acute Myeloid Leukemia
Intervention: Drug: TEN-010
40 Recruiting LY2606368 in Combination With Cytarabine and Fludarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HRMDS)
Condition: Leukemia
Interventions: Drug: Fludarabine;   Drug: Cytarabine;   Drug: LY2606368

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.